Physician profile
Thomas K Hunt
NPI 1013003060
$3,989.01
in general payments reported to CMS, 2019-2025
19 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $160 · 2021: $421 · 2022: $985 · 2023: $977 · 2024: $1,097 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,422.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,030.26 | 2021-2025 | |
| Novo Nordisk INC | $707.20 | 2021-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $479.75 | 2020-2025 | Synjardy, Tradjenta, Jardiance |
| Amgen INC. | $296.90 | 2021-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $285.78 | 2020-2023 | Farxiga, Breztri |
| Lilly USA, LLC | $275.89 | 2020-2024 | Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $184.64 | 2021-2024 | Eliquis |
| Janssen Pharmaceuticals, INC | $135.82 | 2020-2024 | Xarelto |
| Phathom Pharmaceuticals, INC. | $108.60 | 2024-2025 | Voquezna |
| Pfizer INC. | $97.60 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.83 | 2022-2024 | Glassia |
| Astellas Pharma US INC | $63.34 | 2020-2023 | Veozah |
| Mylan Specialty L.P. | $60.90 | 2021-2024 | Yupelri |
| Exact Sciences Corporation | $44.38 | 2023-2024 | Cologuard Collection Kit |
| Grifols USA, LLC | $40.09 | 2020-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $38.24 | 2020-2025 | Bexsero, Shingrix, Penmenvy |
| Bayer Healthcare Pharmaceuticals INC. | $31.47 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.18 | 2021-2023 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $12.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.